|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GAL |
Gene summary for GAL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GAL | Gene ID | 51083 |
| Gene name | galanin and GMAP prepropeptide | |
| Gene Alias | ETL8 | |
| Cytomap | 11q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | P22466 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51083 | GAL | P5T-E | Human | Esophagus | ESCC | 7.98e-43 | 1.22e+00 | 0.1327 |
| 51083 | GAL | P10T-E | Human | Esophagus | ESCC | 3.36e-11 | 3.23e-01 | 0.116 |
| 51083 | GAL | P12T-E | Human | Esophagus | ESCC | 4.45e-03 | 2.22e-01 | 0.1122 |
| 51083 | GAL | P16T-E | Human | Esophagus | ESCC | 2.35e-24 | 6.39e-01 | 0.1153 |
| 51083 | GAL | P19T-E | Human | Esophagus | ESCC | 4.52e-04 | 5.76e-01 | 0.1662 |
| 51083 | GAL | P22T-E | Human | Esophagus | ESCC | 2.35e-16 | 7.16e-01 | 0.1236 |
| 51083 | GAL | P24T-E | Human | Esophagus | ESCC | 1.52e-35 | 1.52e+00 | 0.1287 |
| 51083 | GAL | P28T-E | Human | Esophagus | ESCC | 1.63e-103 | 4.67e+00 | 0.1149 |
| 51083 | GAL | P31T-E | Human | Esophagus | ESCC | 2.56e-02 | 2.54e-01 | 0.1251 |
| 51083 | GAL | P32T-E | Human | Esophagus | ESCC | 7.92e-40 | 1.90e+00 | 0.1666 |
| 51083 | GAL | P37T-E | Human | Esophagus | ESCC | 1.58e-12 | 7.11e-01 | 0.1371 |
| 51083 | GAL | P38T-E | Human | Esophagus | ESCC | 1.11e-08 | 5.00e-01 | 0.127 |
| 51083 | GAL | P40T-E | Human | Esophagus | ESCC | 1.70e-10 | 1.03e+00 | 0.109 |
| 51083 | GAL | P47T-E | Human | Esophagus | ESCC | 5.70e-04 | 2.40e-01 | 0.1067 |
| 51083 | GAL | P49T-E | Human | Esophagus | ESCC | 4.61e-02 | 4.13e-01 | 0.1768 |
| 51083 | GAL | P52T-E | Human | Esophagus | ESCC | 3.07e-23 | 6.53e-01 | 0.1555 |
| 51083 | GAL | P56T-E | Human | Esophagus | ESCC | 6.74e-08 | 1.55e+00 | 0.1613 |
| 51083 | GAL | P62T-E | Human | Esophagus | ESCC | 1.70e-02 | 1.47e-01 | 0.1302 |
| 51083 | GAL | P74T-E | Human | Esophagus | ESCC | 1.86e-23 | 9.61e-01 | 0.1479 |
| 51083 | GAL | P76T-E | Human | Esophagus | ESCC | 3.84e-11 | 3.91e-01 | 0.1207 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:2001236110 | Oral cavity | LP | regulation of extrinsic apoptotic signaling pathway | 63/4623 | 151/18723 | 2.98e-06 | 6.47e-05 | 63 |
| GO:190390216 | Oral cavity | LP | positive regulation of viral life cycle | 19/4623 | 29/18723 | 3.94e-06 | 8.19e-05 | 19 |
| GO:000931417 | Oral cavity | LP | response to radiation | 155/4623 | 456/18723 | 4.12e-06 | 8.49e-05 | 155 |
| GO:1902905110 | Oral cavity | LP | positive regulation of supramolecular fiber organization | 81/4623 | 209/18723 | 4.30e-06 | 8.80e-05 | 81 |
| GO:003010017 | Oral cavity | LP | regulation of endocytosis | 81/4623 | 211/18723 | 6.57e-06 | 1.29e-04 | 81 |
| GO:1902903110 | Oral cavity | LP | regulation of supramolecular fiber organization | 131/4623 | 383/18723 | 1.58e-05 | 2.78e-04 | 131 |
| GO:001819614 | Oral cavity | LP | peptidyl-asparagine modification | 16/4623 | 24/18723 | 1.68e-05 | 2.92e-04 | 16 |
| GO:005109213 | Oral cavity | LP | positive regulation of NF-kappaB transcription factor activity | 61/4623 | 152/18723 | 1.82e-05 | 3.11e-04 | 61 |
| GO:005109015 | Oral cavity | LP | regulation of DNA-binding transcription factor activity | 147/4623 | 440/18723 | 2.00e-05 | 3.35e-04 | 147 |
| GO:003434114 | Oral cavity | LP | response to interferon-gamma | 57/4623 | 141/18723 | 2.63e-05 | 4.21e-04 | 57 |
| GO:000283211 | Oral cavity | LP | negative regulation of response to biotic stimulus | 46/4623 | 108/18723 | 3.31e-05 | 5.02e-04 | 46 |
| GO:000862517 | Oral cavity | LP | extrinsic apoptotic signaling pathway via death domain receptors | 37/4623 | 82/18723 | 4.28e-05 | 6.15e-04 | 37 |
| GO:001827914 | Oral cavity | LP | protein N-linked glycosylation via asparagine | 15/4623 | 23/18723 | 4.61e-05 | 6.51e-04 | 15 |
| GO:0035303110 | Oral cavity | LP | regulation of dephosphorylation | 52/4623 | 128/18723 | 4.98e-05 | 7.01e-04 | 52 |
| GO:0042060110 | Oral cavity | LP | wound healing | 139/4623 | 422/18723 | 7.10e-05 | 9.48e-04 | 139 |
| GO:003109817 | Oral cavity | LP | stress-activated protein kinase signaling cascade | 88/4623 | 247/18723 | 7.39e-05 | 9.68e-04 | 88 |
| GO:0035304110 | Oral cavity | LP | regulation of protein dephosphorylation | 39/4623 | 90/18723 | 8.11e-05 | 1.04e-03 | 39 |
| GO:007134612 | Oral cavity | LP | cellular response to interferon-gamma | 48/4623 | 118/18723 | 9.16e-05 | 1.15e-03 | 48 |
| GO:001908212 | Oral cavity | LP | viral protein processing | 17/4623 | 29/18723 | 1.02e-04 | 1.24e-03 | 17 |
| GO:004508811 | Oral cavity | LP | regulation of innate immune response | 78/4623 | 218/18723 | 1.57e-04 | 1.78e-03 | 78 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| ICAM1 | ITGAL_ITGB2 | ICAM1_ITGAL_ITGB2 | ICAM | Breast | ADJ |
| ICAM2 | ITGAL_ITGB2 | ICAM2_ITGAL_ITGB2 | ICAM | Breast | ADJ |
| ICAM1 | ITGAL | ICAM1_ITGAL | ICAM | Breast | ADJ |
| F11R | ITGAL_ITGB2 | JAM1_ITGAL_ITGB2 | JAM | Breast | ADJ |
| ICAM1 | ITGAL_ITGB2 | ICAM1_ITGAL_ITGB2 | ICAM | Breast | DCIS |
| ICAM2 | ITGAL_ITGB2 | ICAM2_ITGAL_ITGB2 | ICAM | Breast | DCIS |
| ICAM1 | ITGAL | ICAM1_ITGAL | ICAM | Breast | DCIS |
| F11R | ITGAL_ITGB2 | JAM1_ITGAL_ITGB2 | JAM | Breast | DCIS |
| ICAM1 | ITGAL_ITGB2 | ICAM1_ITGAL_ITGB2 | ICAM | Breast | Healthy |
| ICAM2 | ITGAL_ITGB2 | ICAM2_ITGAL_ITGB2 | ICAM | Breast | Healthy |
| ICAM1 | ITGAL | ICAM1_ITGAL | ICAM | Breast | Healthy |
| ICAM1 | ITGAL_ITGB2 | ICAM1_ITGAL_ITGB2 | ICAM | Breast | IDC |
| ICAM2 | ITGAL_ITGB2 | ICAM2_ITGAL_ITGB2 | ICAM | Breast | IDC |
| ICAM1 | ITGAL | ICAM1_ITGAL | ICAM | Breast | IDC |
| F11R | ITGAL_ITGB2 | JAM1_ITGAL_ITGB2 | JAM | Breast | IDC |
| ICAM1 | ITGAL_ITGB2 | ICAM1_ITGAL_ITGB2 | ICAM | Cervix | ADJ |
| ICAM2 | ITGAL_ITGB2 | ICAM2_ITGAL_ITGB2 | ICAM | Cervix | ADJ |
| ICAM1 | ITGAL | ICAM1_ITGAL | ICAM | Cervix | ADJ |
| F11R | ITGAL_ITGB2 | JAM1_ITGAL_ITGB2 | JAM | Cervix | ADJ |
| ICAM1 | ITGAL_ITGB2 | ICAM1_ITGAL_ITGB2 | ICAM | Cervix | CC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GAL | SNV | Missense_Mutation | c.88G>A | p.Glu30Lys | p.E30K | P22466 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| GAL | SNV | Missense_Mutation | c.142N>T | p.Val48Phe | p.V48F | P22466 | protein_coding | deleterious(0) | possibly_damaging(0.595) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GAL | SNV | Missense_Mutation | rs770751421 | c.115G>A | p.Ala39Thr | p.A39T | P22466 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| GAL | SNV | Missense_Mutation | novel | c.62N>T | p.Ser21Phe | p.S21F | P22466 | protein_coding | deleterious(0) | benign(0.202) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| GAL | SNV | Missense_Mutation | rs540782765 | c.340N>A | p.Ala114Thr | p.A114T | P22466 | protein_coding | tolerated(0.22) | benign(0.055) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GAL | SNV | Missense_Mutation | rs762637870 | c.337N>A | p.Ala113Thr | p.A113T | P22466 | protein_coding | tolerated(0.98) | benign(0.003) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
| GAL | SNV | Missense_Mutation | novel | c.50N>T | p.Ala17Val | p.A17V | P22466 | protein_coding | tolerated(0.44) | benign(0.14) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GAL | SNV | Missense_Mutation | rs762637870 | c.337G>A | p.Ala113Thr | p.A113T | P22466 | protein_coding | tolerated(0.98) | benign(0.003) | TCGA-B5-A0JU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GAL | SNV | Missense_Mutation | novel | c.256A>G | p.Ile86Val | p.I86V | P22466 | protein_coding | tolerated(0.77) | benign(0.001) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| GAL | SNV | Missense_Mutation | rs778530092 | c.263N>A | p.Arg88His | p.R88H | P22466 | protein_coding | tolerated(0.39) | benign(0.026) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51083 | GAL | DRUGGABLE GENOME | Selective serotonin reuptake inhibitors | |||
| 51083 | GAL | DRUGGABLE GENOME | CORTISOL | HYDROCORTISONE | 17982695 | |
| 51083 | GAL | DRUGGABLE GENOME | opioids | |||
| 51083 | GAL | DRUGGABLE GENOME | mirtazapine | MIRTAZAPINE | ||
| 51083 | GAL | DRUGGABLE GENOME | DHEA | PRASTERONE | 12195234 | |
| 51083 | GAL | DRUGGABLE GENOME | heroin | DIACETYLMORPHINE | ||
| 51083 | GAL | DRUGGABLE GENOME | IMMUNOTOXIN | 9189270 | ||
| 51083 | GAL | DRUGGABLE GENOME | TRIIODOTHYRONINE | LIOTHYRONINE SODIUM | 12147214 | |
| 51083 | GAL | DRUGGABLE GENOME | ESTRADIOL BENZOATE | 14666144 | ||
| 51083 | GAL | DRUGGABLE GENOME | antidepressants |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |